Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Bayer
University of California, Irvine
ViroMissile, Inc.
Essen Biotech
National Institutes of Health Clinical Center (CC)
MacroGenics
Alliance for Clinical Trials in Oncology
University of Nebraska
Adela, Inc
Perspective Therapeutics
Memorial Sloan Kettering Cancer Center
Ocellaris Pharma, Inc.
Var2 Pharmaceuticals
M.D. Anderson Cancer Center
Stanford University
Mayo Clinic
Tanabe Pharma America, Inc.
Blueprint Medicines Corporation
HiFiBiO Therapeutics
National Institutes of Health Clinical Center (CC)
Actym Therapeutics, Inc.
AVM Biotechnology Inc
Washington University School of Medicine
Travera Inc
Washington University School of Medicine
3B Pharmaceuticals GmbH
GONGCHU Biotechnology Co., Ltd
Lantheus Medical Imaging
Jonsson Comprehensive Cancer Center
Leap Therapeutics, Inc.
University of Pittsburgh
Telix Pharmaceuticals (Innovations) Pty Limited
PharmaMar
University of California, Irvine
Cancer Research UK
Hutchmed
Tempus AI
Chinese University of Hong Kong
Stanford University
Labcorp Corporation of America Holdings, Inc
Mayo Clinic
Stanford University
Cybrexa Therapeutics
Stanford University
TopAlliance Biosciences
Shanghai PerHum Therapeutics Co., Ltd.
Shanghai PerHum Therapeutics Co., Ltd.
Peking University
Taiho Pharmaceutical Co., Ltd.